ResearcherVellore Institute of Technology UniversityActive in the last 2 years
Sivakumar Arumugam
Matched on ORCID iD 0000-0001-8834-8834; OpenAlex author ID A5101864088. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 2
2023: 1 paper · 2024: 1 paper · 2025: 2 papers
Papers 4
- Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s40360-025-01020-z↗
- Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fphar.2025.1635449↗
- Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using comp… Last author DOI 10.1007/s12672-024-01455-6↗
- Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fmed.2023.1107128↗
Closest collaborators
The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Prasanna Srinivasan Ramalingam · 4 shared papers, 2023–2025 · strength 1.02
- Paper Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pan… DOI 10.1007/s12672-024-01455-6↗
- Paper Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma. DOI 10.3389/fmed.2023.1107128↗
- Paper Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma. DOI 10.3389/fphar.2025.1635449↗
- Md Sadique Hussain · 3 shared papers, 2024–2025 · strength 0.76
- Paper Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pan… DOI 10.1007/s12672-024-01455-6↗
- Paper Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma. DOI 10.3389/fphar.2025.1635449↗
- Paper Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. DOI 10.1186/s40360-025-01020-z↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.